Bioequivalence means two drug products deliver the same active ingredient to your body at the same rate and in the same amount. It’s the standard that allows a generic drug to stand in for a brand-name medication. If a generic is bioequivalent to the original, your body absorbs the drug in a way that’s close enough to be clinically indistinguishable, even though the two pills may look different, use different fillers, or come from different manufacturers.
How Bioequivalence Is Measured
Bioequivalence testing comes down to two core measurements taken from blood samples. The first is peak concentration: the highest level of drug that appears in your bloodstream after a dose. This reflects how fast the drug is absorbed. The second is the total amount of drug absorbed over time, measured by tracking blood levels from the moment you take the dose until the drug is fully cleared. Scientists plot these levels on a graph, and the total area under that curve represents how much drug your body actually took in.
The time it takes to reach peak concentration also provides useful information about absorption speed. Together, these three values paint a picture of how a drug behaves once it enters your body. If a generic matches the brand-name product on all of them, the two drugs are considered bioequivalent.
The 80 to 125 Percent Rule
A generic doesn’t have to be perfectly identical to the brand-name drug. Instead, it has to fall within a statistical window. The FDA requires that the 90% confidence interval for the ratio of the generic’s key measurements to the brand-name’s measurements land between 80% and 125%. This sounds like a wide range, but in practice, approved generics cluster much closer to 100%. The confidence interval approach means the agency needs to be statistically confident the true average falls within that range, not just that a single test result does.
This standard applies broadly, but drugs with a narrow therapeutic index (medications where even small dose changes can cause harm or loss of effectiveness) face tighter scrutiny. For these drugs, the FDA requires a more complex four-way crossover study design and demands that the generic’s batch-to-batch variability be comparable to the brand-name product’s. The acceptable range for the actual drug content in each pill also tightens from 90 to 110 percent down to 95 to 105 percent.
How Bioequivalence Studies Work
Most bioequivalence studies use a crossover design. A group of healthy volunteers takes the brand-name drug, goes through a washout period long enough for the drug to leave their system, then takes the generic (or vice versa). Because every participant serves as their own control, the study can detect differences in absorption without needing to account for natural variation between people.
The FDA typically requires testing under fasting conditions. For most oral medications, a second study under fed conditions is also recommended, because food can change how quickly and completely a drug is absorbed. There are exceptions: if both the generic and brand-name product dissolve rapidly, contain a highly soluble and highly permeable drug, and have similar dissolution profiles, the fed study may be waived. Drugs labeled to be taken only on an empty stomach are also exempt from fed testing.
Modified-release products (extended-release tablets, for example) always require both fasting and fed studies, since the way they release drug over time can be more sensitive to the presence of food in the stomach.
Why Bioequivalence Matters for Generic Drugs
When a pharmaceutical company wants to sell a generic version of an existing medication, it files an Abbreviated New Drug Application. The company doesn’t need to repeat the large-scale clinical trials that proved the original drug was safe and effective. Instead, it must demonstrate that its product is bioequivalent to the brand-name drug, called the reference listed drug. This is the regulatory shortcut that makes generics faster and cheaper to bring to market.
The FDA requires applicants to submit data from every bioequivalence study they’ve conducted on the formulation, including studies that failed. This transparency rule prevents companies from selectively reporting only favorable results.
Bioequivalence vs. Therapeutic Equivalence
Bioequivalence is one piece of a larger puzzle. A drug earns a therapeutic equivalence rating only when it meets all of the following: it’s approved as safe and effective, it’s a pharmaceutical equivalent (same dosage form, same route, same amount of the same active ingredient), it’s bioequivalent, it’s properly labeled, and it’s manufactured under current good manufacturing practices.
The FDA publishes these ratings in a resource commonly called the Orange Book. Products rated with a code starting with “A” are considered therapeutically equivalent and can be substituted for each other at the pharmacy. Products starting with “B” are not considered interchangeable. This rating system is what pharmacists and insurance companies rely on when deciding whether to swap a brand-name prescription for a generic.
What Can Affect Bioequivalence
Two pills can contain the same active ingredient in the same amount and still behave differently in the body. The inactive ingredients, called excipients, play a larger role than most people realize. Fillers, binders, coatings, and other additives can alter how quickly a tablet dissolves, how the drug moves through the gut, and how much ultimately reaches the bloodstream. Certain excipients like sugar alcohols and polyethylene glycol can change intestinal permeability and speed up or slow down gut transit time.
These effects are especially pronounced for drugs that dissolve easily but have a harder time crossing the intestinal wall. Because these drugs depend on absorption at specific sites in the gut, anything that pushes them through faster or changes the intestinal lining’s permeability can meaningfully shift how much drug gets absorbed. This is one reason the FDA requires actual bioequivalence testing in people rather than simply comparing ingredient lists.
Global Regulatory Alignment
The FDA and the European Medicines Agency use somewhat different review processes, legislative frameworks, and supporting documentation requirements. The EU offers four separate authorization pathways (national, mutual recognition, decentralized, and centralized), while the U.S. uses a single process. Despite these structural differences, a comparison of generic drug decisions from 2017 to 2020 found 95% agreement between the two agencies on whether to approve a given application. The core scientific standard, demonstrating that the generic performs equivalently to the original in the human body, is fundamentally the same on both sides of the Atlantic.